U.S., Feb. 4 -- ClinicalTrials.gov registry received information related to the study (NCT07383025) titled 'Mavacamten Post-marketing Surveillance in Patients With Obstructive Hypertrophic Cardiomyopathy in Japan' on Jan. 26.
Brief Summary: The purpose of this study is to assess the real-world effectiveness and safety of mavacamten in patients with obstructive hypertrophic cardiomyopathy (HCM) receiving mavacamten in Japan
Study Start Date: May 21, 2025
Study Type: OBSERVATIONAL
Condition:
Obstructive Hypertrophic Cardiomyopathy (oHCM)
Intervention:
DRUG: Mavacamten
According to the product label
Recruitment Status: RECRUITING
Sponsor: Bristol-Myers Squibb
Published by HT Digital Content Services with permission from Health Daily...